M&A / Deals Beeline raises $300m for BMS drugs, and other biofinancings PharmaphorumBeeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week.M&A / DealsRead full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaphorum Beeline Medicines, Oricell, Terremoto, Harbinger, Neomorph, Adcendo, and STORM all closed impressive financing rounds in the last week. M&A / DealsRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Most patients “won’t see benefit” with Alzheimer’s drugsNext: Revolution doubles stock offering target to $2B following pancreatic cancer win Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
